# A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct07567846/  
OnCo record `nct07567846` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GDC-1261 in prostate cancer, run by Genentech, Inc., now recruiting.

## Summary

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07567846 by Genentech, Inc., with 260 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-11-30. Interventions recorded: GDC-1261.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07567846
- Phase: 1/2
- Setting: A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer
- Sponsor: Genentech, Inc.
- Enrolled: 260

## Sources

- ClinicalTrials.gov NCT07567846: https://clinicaltrials.gov/study/NCT07567846

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07567846.json